BioRestorative Therapies receives expanded tissue license from NYSDOH

BioRestorative Therapies (BRTX) announced that it has received a provisional license from the New York State Department of Health, NYSDOH, for the processing of allogeneic donor tissue material for the isolation, expansion and cryopreservation of various cell types, including stem cells, for medical research. Previously, BioRestorative was licensed by the NYSDOH to act as a tissue bank for the processing of mesenchymal stem cells derived from autologous donors only. The expanded license allows BioRestorative to leverage its state-of-the-art cGMP manufacturing capabilities to enable the processing, banking and distribution of clinical grade allogeneic biologics.